Andalusian Initiative in Advanced Therapies Report issue

Government Phase 2 Phase 3
Founded: Granada Spain (2008)

Organization Overview

First Clinical Trial
2010
NCT01257776
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amyotrophic Lateral Sclerosis (Phase 2)

Atherosclerosis (Phase 3)

Cardiomyopathies (Phase 3)

Cardiomyopathy, Dilated (Phase 3)

Coronary Artery Disease (Phase 3)

Coronary Occlusion (Phase 3)

Fecal Incontinence (Phase 2)

Heart Diseases (Phase 3)

Heart Failure (Phase 3)

Ischemia (Phase 2)

Motor Neuron Disease (Phase 2)

Myocardial Ischemia (Phase 3)

Sclerosis (Phase 2)

Ventricular Dysfunction (Phase 3)

Viremia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 5